|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein |
CTD |
PMID:15039284 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization |
ISO |
alvocidib results in increased localization of AIFM1 protein |
CTD |
PMID:12734434 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form |
CTD |
PMID:15039284 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with alvocidib] results in decreased expression of BAD protein |
CTD |
PMID:12231544 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bag1 |
BAG cochaperone 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of BAG1 mRNA; alvocidib results in decreased expression of BAG1 protein; alvocidib results in decreased expression of BAG1 protein alternative form |
CTD |
PMID:10887097 PMID:15972445 |
|
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases cleavage increases expression multiple interactions |
ISO |
alvocidib affects the localization of BAX protein alvocidib results in increased cleavage of BAX protein alvocidib results in increased expression of BAX protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of BAX protein; [alvocidib co-treated with gemcitabine] results in increased expression of BAX protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein; Epothilones promotes the reaction [alvocidib affects the localization of BAX protein] |
CTD |
PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:15770523 PMID:16951203 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression decreases response to substance multiple interactions increases expression |
ISO |
alvocidib results in decreased expression of BCL2 mRNA; alvocidib results in decreased expression of BCL2 protein BCL2 protein mutant form results in decreased susceptibility to alvocidib; BCL2 protein results in decreased susceptibility to alvocidib [alvocidib co-treated with gemcitabine] results in decreased expression of BCL2 protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein]; BCL2 protein results in decreased susceptibility to [alvocidib co-treated with Epothilones] alvocidib results in increased expression of BCL2 |
CTD |
PMID:10887097 PMID:10995888 PMID:12170773 PMID:12517783 PMID:12589031 PMID:12734434 PMID:15770523 PMID:15972445 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of BCL2L1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 protein] alvocidib results in decreased expression of BCL2L1; alvocidib results in decreased expression of BCL2L1 mRNA; alvocidib results in decreased expression of BCL2L1 protein |
CTD |
PMID:12517783 PMID:15039284 PMID:15634644 PMID:16820931 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of BID protein; [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of BID protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of BID protein] |
CTD |
PMID:11464216 PMID:12170773 PMID:12231544 PMID:15634644 PMID:16951203 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression multiple interactions |
ISO |
alvocidib results in decreased expression of BIRC3 mRNA; alvocidib results in decreased expression of BIRC3 protein Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 protein] |
CTD |
PMID:12517783 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in decreased expression of BIRC5 protein; [alvocidib co-treated with PBOX-6] results in decreased expression of BIRC5 protein; alvocidib inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of BIRC5 protein]; alvocidib results in decreased phosphorylation of and results in decreased expression of BIRC5 protein alvocidib results in decreased expression of BIRC5; alvocidib results in decreased expression of BIRC5 mRNA; alvocidib results in decreased expression of BIRC5 protein |
CTD |
PMID:12517783 PMID:12517802 PMID:16012789 PMID:16820931 PMID:20206141 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
alvocidib results in increased expression of BTG2 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Casp3 |
caspase 3 |
affects cleavage multiple interactions increases cleavage increases activity |
ISO EXP |
alvocidib affects the cleavage of CASP3 protein alvocidib inhibits the reaction [Colchicine results in increased activity of CASP3 protein] alvocidib results in increased cleavage of CASP3 protein alvocidib results in increased activity of CASP3 protein [alvocidib co-treated with 7-hydroxystaurosporine] results in increased activity of CASP3 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP3 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of CASP3 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP3 protein; [irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; alvocidib affects the cleavage of and results in increased activity of CASP3 protein; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [romidepsin results in increased activity of CASP3 protein]; alvocidib results in increased cleavage of and results in increased activity of CASP3 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:9808574 PMID:10430095 PMID:10896673 PMID:11482875 PMID:11751522 PMID:12170773 PMID:12231544 PMID:12517783 PMID:12589031 PMID:12941380 PMID:14555534 PMID:15014036 PMID:15634644 PMID:15770523 PMID:16012789 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP8 protein alvocidib results in increased cleavage of CASP8 protein |
CTD |
PMID:10896673 PMID:12231544 PMID:12589031 PMID:15634644 PMID:16012789 PMID:16951203 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
affects cleavage increases activity multiple interactions |
ISO |
alvocidib affects the cleavage of CASP9 protein alvocidib results in increased activity of CASP9 protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP9 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein] |
CTD |
PMID:10896673 PMID:12170773 PMID:15634644 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cbr3 |
carbonyl reductase 3 |
decreases expression |
ISO |
alvocidib results in decreased expression of CBR3 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
alvocidib results in decreased expression of and results in decreased activity of CCNA2 protein |
CTD |
PMID:16731754 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with PBOX-6] results in decreased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; alvocidib results in decreased expression of and results in decreased activity of CCNB1 protein alvocidib results in decreased expression of CCNB1 protein |
CTD |
PMID:10430095 PMID:12517783 PMID:15014036 PMID:16731754 PMID:20206141 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of CCND1 protein alvocidib results in decreased expression of CCND1 protein alvocidib results in decreased activity of CCND1 protein |
CTD |
PMID:9802881 PMID:9829756 PMID:10441105 PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:16905211 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
alvocidib results in decreased expression of CCNE1 protein |
CTD |
PMID:15014036 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with PBOX-6] results in decreased activity of CDK1 protein alvocidib results in decreased expression of CDK1 protein modified form alvocidib results in decreased activity of CDK1 protein |
CTD |
PMID:9427698 PMID:9802881 PMID:12517783 PMID:16905211 PMID:20206141 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression decreases activity multiple interactions |
ISO |
alvocidib results in decreased expression of CDK2 protein modified form alvocidib results in decreased activity of CDK2 protein alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein] |
CTD |
PMID:9802881 PMID:10430095 PMID:12517783 PMID:16905211 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity decreases expression |
ISO |
alvocidib results in decreased activity of CDK4 protein alvocidib results in decreased expression of CDK4 protein |
CTD |
PMID:12517783 PMID:12734434 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
EXP |
alvocidib inhibits the reaction [Colchicine results in increased expression of CDK5 protein] |
CTD |
PMID:12941380 |
|
NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression increases cleavage increases expression affects expression |
ISO |
[alvocidib co-treated with gemcitabine] results in increased expression of CDKN1A protein; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A promoter]; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]] alvocidib results in decreased expression of CDKN1A protein alvocidib results in increased cleavage of CDKN1A protein alvocidib results in increased expression of CDKN1A protein alvocidib affects the expression of CDKN1A protein |
CTD |
PMID:10537362 PMID:12734434 PMID:15014036 PMID:15180955 PMID:15770523 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases cleavage increases expression |
ISO |
alvocidib results in increased cleavage of CDKN1B protein [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of CDKN1B protein |
CTD |
PMID:10537362 PMID:12589031 PMID:15180955 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions decreases expression |
ISO |
alvocidib affects the expression of CFLAR mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein] alvocidib results in decreased expression of CFLAR; alvocidib results in decreased expression of CFLAR protein |
CTD |
PMID:16820931 PMID:16951203 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein |
CTD |
PMID:15039284 |
|
NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
alvocidib affects the localization of CYCS protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of CYCS protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein] |
CTD |
PMID:12170773 PMID:12517783 PMID:15634644 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions |
ISO |
alvocidib affects the localization of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of DIABLO protein; [Imatinib Mesylate co-treated with alvocidib] results in increased secretion of DIABLO protein |
CTD |
PMID:12231544 PMID:12517783 PMID:15039284 PMID:15634644 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression increases response to substance decreases expression |
ISO |
alvocidib results in increased expression of E2F1 protein E2F1 results in increased susceptibility to alvocidib alvocidib results in decreased expression of E2F1 mRNA |
CTD |
PMID:12533675 PMID:21239698 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
H2ax |
H2A.X variant histone |
affects expression |
ISO |
alvocidib affects the expression of H2AX protein |
CTD |
PMID:15078984 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of HMGA1 mRNA |
CTD |
PMID:21239698 |
|
NCBI chr20:7,132,501...7,140,155
Ensembl chr20:7,136,007...7,138,980
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
alvocidib affects the localization of HTRA2 protein |
CTD |
PMID:12517783 |
|
NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] |
CTD |
PMID:23589332 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] |
CTD |
PMID:23589332 |
|
NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with alvocidib] results in increased activity of JUN protein |
CTD |
PMID:12231544 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression decreases phosphorylation |
ISO |
alvocidib results in decreased expression of KIT mRNA; alvocidib results in decreased expression of KIT promoter alvocidib results in decreased phosphorylation of KIT protein |
CTD |
PMID:16740725 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein |
CTD |
PMID:15039284 |
|
NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein] |
CTD |
PMID:15039284 |
|
NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15014036 PMID:15039284 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK14 protein |
CTD |
PMID:15634644 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:15014036 PMID:15039284 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK8 protein; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:15039284 PMID:15634644 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression decreases response to substance decreases expression multiple interactions |
ISO |
alvocidib affects the expression of MCL1 mRNA; alvocidib affects the expression of MCL1 protein MCL1 results in decreased susceptibility to alvocidib alvocidib results in decreased expression of MCL1 mRNA; alvocidib results in decreased expression of MCL1 protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of MCL1 protein; [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of MCL1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 protein] |
CTD |
PMID:10887097 PMID:12231544 PMID:12429644 PMID:12517783 PMID:12533675 PMID:15634644 PMID:15972445 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
alvocidib results in decreased expression of MDM2 mRNA; alvocidib results in decreased expression of MDM2 protein |
CTD |
PMID:12589031 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr11:38,035,306...38,066,185
Ensembl chr11:38,035,450...38,059,950
|
|
G |
Nelfa |
negative elongation factor complex member A |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr14:82,093,837...82,117,913
Ensembl chr14:82,093,837...82,117,906
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions |
ISO |
alvocidib results in increased expression of NFKBIA protein modified form alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form] |
CTD |
PMID:15039284 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of PARP1 protein; [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of PARP1 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of PARP1 protein; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein] |
CTD |
PMID:10430095 PMID:12170773 PMID:12517783 PMID:15039284 PMID:15634644 PMID:15770523 PMID:15972445 PMID:16012789 PMID:20663931 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
EXP |
alvocidib inhibits the reaction [Colchicine results in increased expression of PAWR protein] |
CTD |
PMID:12941380 |
|
NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases activity |
ISO |
alvocidib results in decreased activity of PCNA protein |
CTD |
PMID:10441105 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
alvocidib results in increased expression of PERP mRNA |
CTD |
PMID:21382384 |
|
NCBI chr 1:14,224,392...14,236,838
Ensembl chr 1:14,224,393...14,236,846
|
|
G |
Polr2a |
RNA polymerase II subunit A |
decreases expression multiple interactions decreases phosphorylation |
ISO |
alvocidib results in decreased expression of POLR2A mRNA alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]] Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein] |
CTD |
PMID:15039284 PMID:21239698 PMID:23589332 |
|
NCBI chr10:56,339,277...56,364,888
Ensembl chr10:56,339,284...56,365,084
|
|
G |
Pygb |
glycogen phosphorylase B |
affects binding |
ISO |
PYGB protein binds to alvocidib |
CTD |
PMID:11368340 |
|
NCBI chr 3:146,581,063...146,629,504
Ensembl chr 3:146,582,752...146,634,535
|
|
G |
Pygl |
glycogen phosphorylase L |
affects binding |
ISO |
PYGL protein binds to alvocidib |
CTD |
PMID:11368340 |
|
NCBI chr 6:92,597,759...92,643,734
Ensembl chr 6:92,597,706...92,643,847
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases activity decreases response to substance multiple interactions decreases phosphorylation decreases expression |
ISO |
alvocidib results in decreased activity of RB1 protein modified form RB1 results in decreased susceptibility to alvocidib [docetaxel co-treated with alvocidib] results in decreased phosphorylation of and results in decreased expression of RB1 protein alvocidib results in decreased phosphorylation of RB1 protein alvocidib results in decreased expression of RB1 protein; alvocidib results in decreased expression of RB1 protein modified form |
CTD |
PMID:9829756 PMID:10441105 PMID:15180955 PMID:15297405 PMID:16905211 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of RBL1 protein |
CTD |
PMID:9829756 |
|
NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein alvocidib results in decreased expression of STAT3 mRNA |
CTD |
PMID:15039284 PMID:21239698 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Supt5h |
SPT5 homolog, DSIF elongation factor subunit |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr 1:85,437,780...85,466,854
Ensembl chr 1:85,437,780...85,466,854
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases activity |
ISO |
alvocidib analog results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21204955 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
alvocidib results in increased expression of TNFRSF10A |
CTD |
PMID:16820931 |
|
NCBI chr15:51,433,853...51,464,215
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases response to substance increases expression |
ISO |
[alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein alvocidib results in increased susceptibility to TNFSF10 alvocidib results in increased expression of TNFSF10 |
CTD |
PMID:16820931 PMID:16951203 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions increases expression |
ISO |
alvocidib results in decreased expression of TP53 protein [docetaxel co-treated with alvocidib] results in increased expression of TP53 protein [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of TP53 protein |
CTD |
PMID:9808574 PMID:10537362 PMID:12589031 PMID:15180955 PMID:15297405 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
alvocidib results in decreased expression of VEGFA mRNA |
CTD |
PMID:21239698 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression multiple interactions |
ISO |
alvocidib results in decreased expression of XIAP mRNA; alvocidib results in decreased expression of XIAP protein [irinotecan co-treated with alvocidib] results in increased cleavage of XIAP protein; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP protein] |
CTD |
PMID:10887097 PMID:11751522 PMID:12517783 PMID:15385934 PMID:15972445 PMID:16951203 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance |
ISO |
1-Deoxynojirimycin results in decreased susceptibility to APP protein |
CTD |
PMID:19028522 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased activity of CASP3 protein] |
CTD |
PMID:19028522 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of CD36 mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of CEBPA mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein] |
CTD |
PMID:19028522 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of FBP2 protein] |
CTD |
PMID:25446853 |
|
NCBI chr17:372,554...389,918
Ensembl chr17:372,551...389,967
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of G6PC protein] |
CTD |
PMID:25446853 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GCK protein] |
CTD |
PMID:25446853 |
|
NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:25445511 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of INSR protein] |
CTD |
PMID:25446853 |
|
NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of LPL mRNA] |
CTD |
PMID:25446853 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCX protein] |
CTD |
PMID:25446853 |
|
NCBI chr 1:219,759,157...219,859,854
Ensembl chr 1:219,759,183...219,859,848
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCK1 protein] |
CTD |
PMID:25446853 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] results in increased expression of PDHA1 mRNA |
CTD |
PMID:25446853 |
|
NCBI chr X:37,329,779...37,343,410
Ensembl chr X:37,329,779...37,343,410
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PDK1 mRNA] |
CTD |
PMID:25446853 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pfkp |
phosphofructokinase, platelet |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PFKP protein] |
CTD |
PMID:25446853 |
|
NCBI chr17:68,510,765...68,574,387
Ensembl chr17:68,511,064...68,559,471
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PKLR protein] |
CTD |
PMID:25446853 |
|
NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Dietary Fats] results in increased expression of PPARGC1B mRNA |
CTD |
PMID:25445511 |
|
NCBI chr18:56,626,725...56,650,524
Ensembl chr18:56,626,712...56,728,968
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression decreases activity |
ISO |
Haloperidol inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCB1 mRNA Haloperidol results in decreased activity of ABCB1 protein |
CTD |
PMID:15946544 PMID:16810505 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCC1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Haloperidol inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Adam1a |
ADAM metallopeptidase domain 1a |
decreases expression |
EXP |
Haloperidol results in decreased expression of ADAM1A mRNA |
CTD |
PMID:16715494 |
|
NCBI chr12:40,533,731...40,536,632
Ensembl chr12:40,533,632...40,536,620
|
|
G |
Adcy5 |
adenylate cyclase 5 |
affects response to substance multiple interactions |
ISO |
ADCY5 protein affects the susceptibility to Haloperidol SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Haloperidol] |
CTD |
PMID:12223546 |
|
NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
ISO |
Haloperidol affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adora2a |
adenosine A2a receptor |
affects response to substance |
ISO |
ADORA2A protein affects the susceptibility to Haloperidol |
CTD |
PMID:11172060 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of AGPAT1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:4,369,399...4,378,272
Ensembl chr20:4,369,178...4,378,269
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AKT1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases expression |
EXP |
Haloperidol results in increased expression of AKT2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Ap2a2 |
adaptor related protein complex 2 subunit alpha 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AP2A2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:214,534,217...214,607,497
Ensembl chr 1:214,534,284...214,606,169
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
affects expression |
EXP |
Haloperidol affects the expression of AP2B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:70,516,462...70,621,973
Ensembl chr10:70,520,206...70,621,977
|
|
G |
Apod |
apolipoprotein D |
increases expression |
ISO |
Haloperidol results in increased expression of APOD mRNA |
CTD |
PMID:14647396 |
|
NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ARC mRNA 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of ARC mRNA] |
CTD |
PMID:18208916 PMID:19695244 |
|
NCBI chr 7:115,907,097...115,911,059
Ensembl chr 7:115,907,097...115,910,541
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:140,412,463...140,438,751
Ensembl chr 7:140,398,199...140,437,467
|
|
G |
Arl3 |
ADP ribosylation factor like GTPase 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:266,287,015...266,333,099
Ensembl chr 1:266,287,017...266,333,105
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL5A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:37,922,544...37,947,434
Ensembl chr 3:37,924,793...37,947,283
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
increases expression |
ISO |
Haloperidol results in increased expression of ARPC4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:145,330,457...145,340,985
Ensembl chr 4:145,330,457...145,340,984
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Haloperidol results in decreased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1B2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:56,205,622...56,211,879
Ensembl chr10:56,205,625...56,211,891
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:104,190,032...104,221,342
Ensembl chr 8:104,190,032...104,221,342
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:16465460 |
|
NCBI chr16:22,326,537...22,350,143
Ensembl chr16:22,326,529...22,350,155
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AXIN2 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of BAX protein Haloperidol results in increased expression of BAX mRNA; Haloperidol results in increased expression of BAX protein |
CTD |
PMID:16462815 PMID:17069804 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Haloperidol results in increased expression of BCL2 protein |
CTD |
PMID:17069804 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression decreases expression |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein] Haloperidol results in increased expression of BCL2L1 protein |
CTD |
PMID:16462815 PMID:17805306 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression decreases expression |
EXP ISO |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; Haloperidol inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] Haloperidol results in increased expression of BDNF mRNA Haloperidol results in increased expression of BDNF protein Haloperidol inhibits the reaction [Cocaine results in decreased expression of BDNF protein] Haloperidol results in decreased expression of BDNF mRNA; Haloperidol results in decreased expression of BDNF protein |
CTD |
PMID:11488957 PMID:12393228 PMID:12478621 PMID:15168214 PMID:17442543 PMID:17805306 PMID:18208916 PMID:20554863 PMID:29182611 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
affects expression |
EXP |
Haloperidol affects the expression of BET1L mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:213,602,836...213,606,507
Ensembl chr 1:213,602,850...213,605,643
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
decreases expression |
ISO |
Haloperidol results in decreased expression of BPTF mRNA |
CTD |
PMID:14647396 |
|
NCBI chr10:95,248,573...95,350,162
Ensembl chr10:95,250,294...95,349,789
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
decreases expression |
EXP ISO |
Haloperidol results in decreased expression of CACNA1A mRNA |
CTD |
PMID:14647396 PMID:16715494 |
|
NCBI chr19:25,453,236...25,749,550
Ensembl chr19:25,526,751...25,749,550
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
affects activity |
EXP |
Haloperidol affects the activity of CALCA protein |
CTD |
PMID:10075105 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Haloperidol results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol results in decreased expression of and results in decreased phosphorylation of CAMK2A protein Haloperidol results in increased expression of CAMK2A mRNA Haloperidol results in decreased expression of CAMK2A protein |
CTD |
PMID:15860345 PMID:18061412 PMID:19289156 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2D mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:230,900,907...231,132,207
Ensembl chr 2:230,901,126...231,132,039
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of CAMK4 protein Haloperidol results in increased expression of CAMK4 mRNA |
CTD |
PMID:15860345 PMID:19289156 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr10:59,585,023...59,608,180
Ensembl chr10:59,585,072...59,608,165
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr12:39,253,409...39,302,601
Ensembl chr12:39,253,409...39,302,601
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:15168214 PMID:17805306 PMID:18590723 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions decreases expression decreases activity |
EXP |
Carvedilol inhibits the reaction [Haloperidol results in decreased expression of CAT protein]; Haloperidol results in decreased activity of and results in decreased expression of CAT protein; Zolpidem inhibits the reaction [Haloperidol results in decreased activity of CAT] |
CTD |
PMID:12010767 PMID:12482469 PMID:16564057 PMID:17513028 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cck |
cholecystokinin |
increases expression |
EXP |
Haloperidol results in increased expression of CCK mRNA |
CTD |
PMID:10974607 |
|
NCBI chr 8:130,120,525...130,127,515
Ensembl chr 8:130,120,523...130,127,392
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CCND1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Haloperidol results in increased expression of CCND3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
EXP |
Haloperidol results in increased expression of CCNL1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:157,747,295...157,759,838
Ensembl chr 2:157,747,542...157,759,838
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
EXP |
Haloperidol results in increased expression of CDC42 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
|
|
G |
Chl1 |
cell adhesion molecule L1-like |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHL1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:70,269,414...70,331,313
Ensembl chr 4:70,252,366...70,330,803
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:60,512,360...60,668,413
Ensembl chr 3:60,513,077...60,611,924
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
ISO |
CHRM4 affects the susceptibility to Haloperidol |
CTD |
PMID:21269601 |
|
NCBI chr 3:80,833,272...80,841,165
Ensembl chr 3:80,833,272...80,841,006
|
|
G |
Cldn11 |
claudin 11 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CLDN11 mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 2:115,823,541...115,836,846
Ensembl chr 2:115,823,538...115,836,846
|
|
G |
Clta |
clathrin, light chain A |
affects expression |
EXP |
Haloperidol affects the expression of CLTA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:59,490,689...59,509,139
Ensembl chr 5:59,491,096...59,509,138
|
|
G |
Cltb |
clathrin, light chain B |
decreases expression |
EXP |
Haloperidol results in decreased expression of CLTB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:10,537,348...10,554,999
Ensembl chr17:10,537,365...10,554,989
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr10:88,490,798...88,497,357
Ensembl chr10:88,490,798...88,497,356
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:28017790 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Coil |
coilin |
increases expression |
EXP |
Haloperidol results in increased expression of COIL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:76,320,676...76,336,169
Ensembl chr10:76,320,041...76,341,418
|
|
G |
Cpn1 |
carboxypeptidase N subunit 1 |
increases expression |
EXP |
Haloperidol results in increased expression of CPN1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:263,733,887...263,762,758
Ensembl chr 1:263,733,519...263,762,785
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases activity increases phosphorylation |
ISO EXP |
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of CREB1 protein] Amphetamine affects the reaction [Haloperidol results in increased activity of CREB1 protein modified form] |
CTD |
PMID:12125044 PMID:12871586 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of CRHBP mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:25,141,471...25,153,334
Ensembl chr 2:25,141,471...25,153,334
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRY1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr 7:24,534,593...24,634,098
Ensembl chr 7:24,534,615...24,634,097
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CSNK2A1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 3:147,713,808...147,760,375
Ensembl chr 3:147,713,821...147,757,862
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Haloperidol results in increased expression of CST3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:143,219,671...143,223,544
Ensembl chr 3:143,219,686...143,223,615
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Haloperidol results in decreased expression of CTNNB1 mRNA Haloperidol results in increased expression of CTNNB1 protein DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 PMID:18797397 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
EXP |
Haloperidol results in increased expression of CTRL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr19:37,905,864...37,907,714
Ensembl chr19:37,905,864...37,907,714
|
|
G |
Ctsk |
cathepsin K |
increases expression |
EXP |
Haloperidol results in increased expression of CTSK mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 protein polymorphism affects the susceptibility to Haloperidol |
CTD |
PMID:15538130 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Dcaf6 |
DDB1 and CUL4 associated factor 6 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DCAF6 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr13:83,578,730...83,680,330
Ensembl chr13:83,579,036...83,680,207
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of DCLK1 mRNA |
CTD |
PMID:15860345 PMID:18797397 |
|
NCBI chr 2:144,646,255...144,939,389
Ensembl chr 2:144,646,308...144,936,927
|
|
G |
Dennd10 |
DENN domain containing 10 |
increases expression |
EXP |
Haloperidol results in increased expression of DENND10 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:282,188,080...282,211,588
Ensembl chr 1:282,188,110...282,210,580
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
increases expression |
ISO |
Haloperidol results in increased expression of DEPP1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:148,780,330...148,784,566
Ensembl chr 4:148,782,479...148,784,562
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of DGKA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:3,143,826...3,170,764
Ensembl chr 7:3,143,827...3,170,146
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
decreases expression |
EXP |
Haloperidol results in decreased expression of DLAT mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:55,062,549...55,087,832
Ensembl chr 8:55,062,551...55,087,832
|
|
G |
Dpf1 |
double PHD fingers 1 |
increases expression |
ISO |
Haloperidol results in increased expression of DPF1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:87,248,448...87,258,070
Ensembl chr 1:87,248,489...87,258,070
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding increases expression decreases expression affects activity |
ISO EXP |
Haloperidol binds to DRD1 protein Haloperidol results in increased expression of DRD1 protein Haloperidol results in decreased expression of DRD1 mRNA Haloperidol affects the activity of DRD1 protein |
CTD |
PMID:8750706 PMID:8794996 PMID:12887421 PMID:16983399 PMID:23611293 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding affects activity multiple interactions increases expression affects response to substance |
ISO EXP |
DRD2 protein binds to Haloperidol; DRD2 protein binds to Haloperidol analog; Haloperidol binds to DRD2 protein Haloperidol affects the activity of DRD2 protein [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; cyclo(leucylglycine) inhibits the reaction [Haloperidol results in increased expression of DRD2 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein]; felbamate inhibits the reaction [Haloperidol affects the activity of DRD2 protein]; Haloperidol binds to and results in decreased activity of DRD2 protein; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol inhibits the reaction [iodosulpride binds to DRD2 protein]; Haloperidol inhibits the reaction [Spiperone binds to DRD2 protein]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; zinc chloride inhibits the reaction [Haloperidol binds to DRD2 protein] Haloperidol results in increased expression of DRD2; Haloperidol results in increased expression of DRD2 mRNA; Haloperidol results in increased expression of DRD2 protein Haloperidol binds to DRD2; Haloperidol binds to DRD2 protein; Haloperidol binds to DRD2 protein alternative form [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Ethanol; [Haloperidol results in increased expression of DRD2 protein] which results in decreased susceptibility to Pentobarbital; Haloperidol binds to and results in decreased activity of DRD2 protein DRD2 affects the susceptibility to Haloperidol; DRD2 protein affects the susceptibility to Haloperidol Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 mRNA]; Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 protein] |
CTD |
PMID:1351265 PMID:1361536 PMID:1380082 PMID:2945998 PMID:7845605 PMID:7878047 PMID:8115415 PMID:8200438 PMID:8794996 PMID:9109525 PMID:9808703 PMID:10720636 PMID:10936494 PMID:11172060 PMID:11927170 PMID:11997696 PMID:12191584 PMID:12476322 PMID:14552778 PMID:15716360 PMID:16033416 PMID:16144542 PMID:18295747 PMID:19120057 PMID:20361897 PMID:20730801 PMID:23611293 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Drd3 |
dopamine receptor D3 |
affects binding |
ISO |
DRD3 protein binds to Haloperidol analog |
CTD |
PMID:14552778 |
|
NCBI chr11:61,819,102...61,883,223
Ensembl chr11:61,822,077...61,874,327
|
|
G |
Drd4 |
dopamine receptor D4 |
affects activity |
ISO |
Haloperidol affects the activity of DRD4 protein |
CTD |
PMID:23611293 |
|
NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
|
|
G |
Drp2 |
dystrophin related protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of DRP2 mRNA alternative form |
CTD |
PMID:16715494 |
|
NCBI chr X:105,239,623...105,290,233
Ensembl chr X:105,239,620...105,289,808
|
|
G |
Dtnbp1 |
dystrobrevin binding protein 1 |
increases response to substance affects response to substance |
ISO |
DTNBP1 gene polymorphism results in increased susceptibility to Haloperidol DTNBP1 protein affects the susceptibility to Haloperidol |
CTD |
PMID:19369910 |
|
NCBI chr17:20,090,136...20,182,332
Ensembl chr17:20,090,246...20,182,206
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:84,051,177...84,068,479
Ensembl chr11:84,051,078...84,068,302
|
|
G |
Egr1 |
early growth response 1 |
affects expression multiple interactions increases expression |
EXP ISO |
Haloperidol affects the expression of EGR1 protein Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]; OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] Haloperidol results in increased expression of EGR1 mRNA; Haloperidol results in increased expression of EGR1 protein |
CTD |
PMID:12243769 PMID:16452686 PMID:17028028 PMID:17913375 PMID:18208916 PMID:19695244 PMID:20184921 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
affects expression increases expression decreases expression |
ISO EXP |
Haloperidol affects the expression of EGR2 mRNA Haloperidol results in increased expression of EGR2 mRNA Haloperidol results in decreased expression of EGR2 protein |
CTD |
PMID:17028028 PMID:18208916 PMID:19401217 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases phosphorylation multiple interactions |
ISO EXP |
Haloperidol results in increased phosphorylation of ELK1 protein SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] Nifedipine affects the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:12871586 PMID:17913375 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Eno1 |
enolase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ENO1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:17805306 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Haloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ERBB4 protein Haloperidol results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
affects response to substance |
ISO |
FABP3 affects the susceptibility to Haloperidol |
CTD |
PMID:20181611 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Haloperidol results in increased expression of FASN mRNA |
CTD |
PMID:16027736 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Haloperidol results in increased expression of FNDC4 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:26,387,284...26,389,524
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin affects the reaction [Haloperidol results in increased expression of FOS protein]; Dizocilpine Maleate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; ifenprodil inhibits the reaction [Haloperidol results in increased expression of FOS protein]; tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]; traxoprodil mesylate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; WAY 100135 inhibits the reaction [tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]] Haloperidol results in increased expression of FOS mRNA; Haloperidol results in increased expression of FOS protein Haloperidol results in decreased expression of FOS mRNA; Haloperidol results in decreased expression of FOS protein 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; Clozapine affects the reaction [Haloperidol results in increased expression of FOS protein]; Dronabinol promotes the reaction [Haloperidol results in increased expression of FOS protein]; Nifedipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Nimodipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Propranolol inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Theophylline inhibits the reaction [Haloperidol results in increased expression of FOS mRNA] |
CTD |
PMID:1393566 PMID:9571656 PMID:9748542 PMID:10199625 PMID:10435392 PMID:11166331 PMID:11409749 PMID:11440804 PMID:11516571 PMID:11602683 PMID:11997696 PMID:12093589 PMID:12125044 PMID:12243769 PMID:12464447 PMID:15120589 PMID:15140647 PMID:17028028 PMID:17913375 PMID:18208916 PMID:18295747 PMID:18521575 PMID:18585397 PMID:18789920 PMID:19352073 PMID:19695244 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Haloperidol results in increased expression of FOSB protein alternative form Haloperidol results in increased expression of FOSB modified form; Haloperidol results in increased expression of FOSB mRNA; Haloperidol results in increased expression of FOSB protein 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOSB mRNA] |
CTD |
PMID:8714707 PMID:11180499 PMID:12243769 PMID:15579174 PMID:19695244 PMID:24067299 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Amphetamine affects the reaction [Haloperidol results in increased expression of FOSL1 protein] Haloperidol results in increased expression of FOSL1 mRNA; Haloperidol results in increased expression of FOSL1 protein |
CTD |
PMID:12125044 PMID:18208916 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Haloperidol results in increased expression of FOSL2 mRNA |
CTD |
PMID:12243769 |
|
NCBI chr 6:25,598,936...25,616,995
Ensembl chr 6:25,598,936...25,616,995
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions increases phosphorylation affects response to substance |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] Haloperidol results in increased phosphorylation of FYN protein FYN protein affects the susceptibility to Haloperidol |
CTD |
PMID:16407246 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of GABRA1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of GABRB3 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions increases expression decreases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein Haloperidol results in increased expression of GAD1 mRNA Haloperidol results in decreased expression of GAD1 mRNA; Haloperidol results in decreased expression of GAD1 protein |
CTD |
PMID:12887421 PMID:14519413 PMID:15061247 PMID:15967061 PMID:18923069 PMID:19359144 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GAD2 mRNA; Haloperidol results in decreased expression of GAD2 protein Haloperidol results in increased expression of GAD2 mRNA |
CTD |
PMID:18923069 PMID:19359144 |
|
NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
EXP |
Haloperidol results in increased expression of GAPDH mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Haloperidol results in increased expression of GDPD3 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:198,199,032...198,209,178
Ensembl chr 1:198,199,622...198,209,150
|
|
G |
Gimap5 |
GTPase, IMAP family member 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GIMAP5 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 4:78,377,228...78,386,683
Ensembl chr 4:78,378,144...78,385,577
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GJA1 protein |
CTD |
PMID:18585900 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Haloperidol results in decreased expression of GLUL mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Gna12 |
G protein subunit alpha 12 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNA12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:15,890,202...15,971,212
Ensembl chr12:15,890,170...15,971,212
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:13,405,136...13,486,866
Ensembl chr 4:13,405,136...13,485,883
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
|
|
G |
Gnas |
GNAS complex locus |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483 Ensembl chr 3:172,374,957...172,428,483
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [manganese chloride results in increased secretion of GNRH1 protein] |
CTD |
PMID:18603625 |
|
NCBI chr15:44,441,856...44,446,064
Ensembl chr15:44,442,555...44,442,875 Ensembl chr15:44,442,555...44,442,875
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
affects expression |
EXP |
Haloperidol affects the expression of GOT2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:9,587,637...9,613,323
Ensembl chr19:9,587,653...9,613,340
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of GPX1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIA1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
increases expression |
EXP |
Haloperidol results in increased expression of GRIK2 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr20:53,791,428...54,517,691
Ensembl chr20:53,789,760...54,517,709
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
increases expression |
EXP |
Haloperidol results in increased expression of GRIK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:46,804,134...47,237,546
Ensembl chr 8:46,806,147...47,094,352
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of GRIK5 mRNA |
CTD |
PMID:14647396 PMID:15860345 |
|
NCBI chr 1:81,885,516...81,946,731
Ensembl chr 1:81,885,521...81,946,714
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GRIN1 mRNA Haloperidol results in increased expression of GRIN1 mRNA |
CTD |
PMID:12020038 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIN2A mRNA; Haloperidol results in decreased expression of GRIN2A protein |
CTD |
PMID:12608697 PMID:15860345 PMID:18061412 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions increases phosphorylation |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] |
CTD |
PMID:16407246 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
Haloperidol results in increased expression of GRIN2C mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:103,798,290...103,816,923
Ensembl chr10:103,798,291...103,816,287
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIN2D mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
|
|
G |
Grin3b |
glutamate ionotropic receptor NMDA type subunit 3B |
increases expression |
EXP |
Haloperidol results in increased expression of GRIN3B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:12,764,993...12,771,310
Ensembl chr 7:12,764,993...12,771,310
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRK6 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr17:9,705,917...9,721,921
Ensembl chr17:9,703,453...9,721,574
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
increases expression |
EXP |
Haloperidol results in increased expression of GRM1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:4,753,141...5,165,859
Ensembl chr 1:4,753,144...5,165,859
|
|
G |
Grm2 |
glutamate metabotropic receptor 2 |
increases expression |
EXP |
Haloperidol results in increased expression of GRM2 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 8:115,344,999...115,358,628
Ensembl chr 8:115,344,999...115,358,046
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of GSK3A protein DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein] |
CTD |
PMID:16144542 |
|
NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein] Haloperidol results in increased expression of GSK3B mRNA; Haloperidol results in increased expression of GSK3B protein |
CTD |
PMID:16144542 PMID:19359144 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
EXP |
Haloperidol results in increased expression of GSTM1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GSTM2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [GSTP1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of GSTP1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Higd1a |
HIG1 hypoxia inducible domain family, member 1A |
increases expression |
ISO |
Haloperidol results in increased expression of HIGD1A mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:130,482,492...130,491,888
Ensembl chr 8:130,482,493...130,491,998
|
|
G |
Hist2h2aa2 |
histone cluster 2 H2A family member A2 |
increases expression |
ISO |
Haloperidol results in increased expression of H2AC18 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:198,381,678...198,382,247
Ensembl chr 2:198,388,809...198,389,201 Ensembl chr 2:198,388,809...198,389,201
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases activity increases expression multiple interactions |
ISO |
Haloperidol results in increased activity of HMGCR protein Haloperidol results in increased expression of HMGCR mRNA [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Triglycerides |
CTD |
PMID:16027736 PMID:17052361 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of HMGCS1 mRNA |
CTD |
PMID:16027736 PMID:17052361 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions increases expression |
EXP |
Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA] |
CTD |
PMID:12464447 PMID:15860345 PMID:20147574 |
|
NCBI chr 2:22,909,550...23,012,303
Ensembl chr 2:22,909,569...23,009,678
|
|
G |
Hpcal4 |
hippocalcin-like 4 |
decreases expression |
EXP |
Haloperidol results in decreased expression of HPCAL4 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 5:140,870,127...140,882,242
Ensembl chr 5:140,870,140...140,882,244
|
|
G |
Hspg2 |
heparan sulfate proteoglycan 2 |
decreases expression multiple interactions |
ISO |
Haloperidol results in decreased expression of HSPG2 mRNA HSPG2 gene results in increased susceptibility to [Haloperidol co-treated with Reserpine] |
CTD |
PMID:20072119 |
|
NCBI chr 5:155,812,096...155,913,751
|
|
G |
Htr1d |
5-hydroxytryptamine receptor 1D |
decreases expression |
EXP |
Haloperidol results in decreased expression of HTR1D mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:154,780,958...154,801,505
Ensembl chr 5:154,800,226...154,801,350
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects binding multiple interactions |
EXP ISO |
Haloperidol binds to HTR2A protein [Phencyclidine co-treated with Haloperidol] affects the activity of HTR2A protein |
CTD |
PMID:7520908 PMID:12191584 PMID:15380371 |
|
NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
decreases expression |
EXP |
Haloperidol results in decreased expression of HTR2C mRNA |
CTD |
PMID:17868938 |
|
NCBI chr X:118,084,520...118,318,040
Ensembl chr X:118,084,890...118,318,039
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of ID2 mRNA Haloperidol results in increased expression of ID2 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Ilkap |
ILK associated serine/threonine phosphatase |
decreases expression |
EXP |
Haloperidol results in decreased expression of ILKAP mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:98,514,599...98,536,586
Ensembl chr 9:98,514,584...98,536,581
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of INHA mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Haloperidol results in increased expression of INHBE mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression decreases expression |
EXP |
Haloperidol results in increased expression of JUN mRNA; Haloperidol results in increased expression of JUN protein Haloperidol results in decreased expression of JUN mRNA |
CTD |
PMID:12093589 PMID:12125044 PMID:15860345 PMID:18208916 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of JUNB mRNA] Haloperidol results in decreased expression of JUNB mRNA |
CTD |
PMID:12093589 PMID:19695244 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
Haloperidol results in increased expression of KCNA1 mRNA; Haloperidol results in increased expression of KCNA1 protein |
CTD |
PMID:18797397 |
|
NCBI chr 4:159,190,781...159,192,526
Ensembl chr 4:159,190,804...159,192,526
|
|
G |
Kcnab1 |
potassium voltage-gated channel subfamily A member regulatory beta subunit 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KCNAB1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:155,555,798...156,011,438
Ensembl chr 2:155,718,359...156,009,526
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Haloperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Haloperidol results in decreased activity of KCNH2 protein |
CTD |
PMID:15671647 PMID:16278312 PMID:16494862 PMID:19583963 PMID:21158687 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnip3 |
potassium voltage-gated channel interacting protein 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KCNIP3 mRNA; Haloperidol results in decreased expression of KCNIP3 protein |
CTD |
PMID:18797397 |
|
NCBI chr 3:120,023,062...120,087,650
Ensembl chr 3:120,023,917...120,087,136
|
|
G |
Klc1 |
kinesin light chain 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KLC1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:136,330,151...136,373,716
Ensembl chr 6:136,330,383...136,373,721
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
decreases expression |
ISO |
Haloperidol results in decreased expression of KMT2A mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:49,110,407...49,185,872
Ensembl chr 8:49,114,990...49,158,971
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases expression |
EXP |
Haloperidol results in increased expression of KRAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Lamtor3 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 |
increases expression |
ISO |
Haloperidol results in increased expression of LAMTOR3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:243,160,821...243,173,057
Ensembl chr 2:243,160,917...243,173,048
|
|
G |
Ldhb |
lactate dehydrogenase B |
decreases expression increases expression |
ISO EXP |
Haloperidol results in decreased expression of LDHB mRNA Haloperidol results in increased expression of LDHB mRNA |
CTD |
PMID:15860345 PMID:16465460 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Haloperidol results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
LOC103690091 |
proSAAS |
increases expression |
ISO |
Haloperidol results in increased expression of PCSK1N mRNA |
CTD |
PMID:14647396 |
|
NCBI chr X:15,324,261...15,328,617
|
|
G |
LOC299277 |
similar to serine (or cysteine) peptidase inhibitor, clade A, member 3B |
increases expression |
ISO |
Haloperidol results in increased expression of SERPINA3 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:127,871,895...127,888,287
Ensembl chr 6:127,872,666...127,886,540
|
|
G |
Mag |
myelin-associated glycoprotein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MAG mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 1:89,345,325...89,360,905
Ensembl chr 1:89,345,429...89,360,733
|
|
G |
Map1a |
microtubule-associated protein 1A |
increases expression |
EXP |
Haloperidol results in increased expression of MAP1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAP2K1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases expression increases expression |
EXP ISO |
Haloperidol results in decreased expression of MAP2K2 mRNA Haloperidol results in increased expression of MAP2K2 mRNA |
CTD |
PMID:14647396 PMID:15860345 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:68,055,976...68,282,656
Ensembl chr 8:68,055,972...68,282,590
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP3K1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:43,329,516...43,393,203
Ensembl chr 2:43,329,516...43,393,207
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP3K12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:144,102,275...144,120,306
Ensembl chr 7:144,102,680...144,109,116
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation decreases expression multiple interactions |
ISO EXP |
Haloperidol results in increased phosphorylation of MAPK1 protein Haloperidol results in decreased expression of MAPK1 mRNA [potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12871586 PMID:15860345 PMID:28017790 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK14 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Haloperidol results in increased phosphorylation of MAPK3 protein [potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12871586 PMID:28017790 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk6 |
mitogen-activated protein kinase 6 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:82,328,013...82,351,108
Ensembl chr 8:82,328,020...82,351,108
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
EXP |
Haloperidol results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:17092607 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK9 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAS1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:48,076,761...48,108,218
Ensembl chr 1:48,077,033...48,108,216
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MBP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mchr1 |
melanin-concentrating hormone receptor 1 |
affects binding |
ISO |
Haloperidol binds to MCHR1 protein |
CTD |
PMID:16983399 |
|
NCBI chr 7:122,456,846...122,459,324
Ensembl chr 7:122,456,799...122,459,960
|
|
G |
Mog |
myelin oligodendrocyte glycoprotein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MOG mRNA |
CTD |
PMID:17177202 |
|
NCBI chr20:2,003,871...2,014,284
Ensembl chr20:2,004,052...2,014,286
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
Haloperidol results in decreased expression of NCAN mRNA |
CTD |
PMID:18797397 |
|
NCBI chr16:21,050,243...21,076,707
Ensembl chr16:21,050,243...21,076,707
|
|
G |
Ncl |
nucleolin |
increases expression |
ISO |
Haloperidol results in increased expression of NCL mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 9:93,369,119...93,377,643
Ensembl chr 9:93,368,932...93,377,643
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
ISO |
Haloperidol results in decreased expression of NEDD4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 8:79,323,408...79,408,842
Ensembl chr 8:79,323,408...79,408,833
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of NFKB1 protein |
CTD |
PMID:16500086 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Haloperidol results in decreased expression of NGFR mRNA |
CTD |
PMID:16513140 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nop53 |
NOP53 ribosome biogenesis factor |
increases expression |
ISO |
Haloperidol results in increased expression of NOP53 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:77,836,522...77,843,991
Ensembl chr 1:77,836,196...77,844,189
|
|
G |
Nppa |
natriuretic peptide A |
affects activity |
EXP |
Haloperidol affects the activity of NPPA protein modified form |
CTD |
PMID:1363893 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nptx2 |
neuronal pentraxin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of NPTX2 mRNA |
CTD |
PMID:18208916 |
|
NCBI chr12:12,014,638...12,025,547
Ensembl chr12:12,013,911...12,025,549
|
|
G |
Npy |
neuropeptide Y |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol promotes the reaction [Amphetamine results in decreased expression of NPY protein] Haloperidol results in increased expression of NPY protein Haloperidol results in decreased expression of NPY mRNA |
CTD |
PMID:7644023 PMID:15985714 PMID:16516965 |
|
NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Haloperidol results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
increases expression |
EXP |
Haloperidol results in increased expression of NR1D1 mRNA |
CTD |
PMID:11564422 |
|
NCBI chr10:86,683,875...86,690,815
Ensembl chr10:86,683,875...86,690,815
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
affects response to substance multiple interactions increases expression decreases expression |
ISO EXP |
NR4A1 affects the susceptibility to Haloperidol 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of NR4A1 mRNA] Haloperidol results in decreased expression of NR4A1 mRNA |
CTD |
PMID:10987852 PMID:11564422 PMID:14603264 PMID:19695244 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
EXP |
Haloperidol results in increased expression of NR4A3 mRNA |
CTD |
PMID:19695244 |
|
NCBI chr 5:63,781,801...63,822,890
Ensembl chr 5:63,781,801...63,821,637
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
EXP |
Haloperidol results in increased expression of NRG1 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
decreases expression |
EXP |
Haloperidol results in decreased expression of NSF mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:91,879,608...91,986,242
Ensembl chr10:91,878,633...92,008,082
|
|
G |
Nts |
neurotensin |
multiple interactions increases expression |
ISO EXP |
SLC6A3 protein promotes the reaction [Haloperidol results in increased expression of NTS mRNA] Haloperidol results in increased expression of NTS mRNA; Haloperidol results in increased expression of NTS protein 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of NTS mRNA]; Theophylline inhibits the reaction [Haloperidol results in increased expression of NTS mRNA] |
CTD |
PMID:10199625 PMID:11120399 PMID:11602683 PMID:12887421 PMID:14603264 PMID:14698760 |
|
NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
|
|
G |
Numbl |
NUMB-like, endocytic adaptor protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of NUMBL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 1:84,067,841...84,091,659
Ensembl chr 1:84,067,938...84,091,671
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Haloperidol results in increased expression of NUPR1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
affects response to substance |
ISO |
OPRL1 affects the susceptibility to Haloperidol |
CTD |
PMID:16237164 |
|
NCBI chr 3:177,223,779...177,231,663
Ensembl chr 3:177,225,737...177,231,663
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] |
CTD |
PMID:20184921 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Osbpl8 |
oxysterol binding protein-like 8 |
increases expression |
ISO |
Haloperidol results in increased expression of OSBPL8 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:53,878,906...54,030,110
Ensembl chr 7:53,878,610...54,027,892
|
|
G |
Park7 |
Parkinsonism associated deglycase |
increases expression |
ISO |
Haloperidol results in increased expression of PARK7 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Pde10a |
phosphodiesterase 10A |
increases expression |
EXP |
Haloperidol results in increased expression of PDE10A mRNA; Haloperidol results in increased expression of PDE10A protein |
CTD |
PMID:18222493 |
|
NCBI chr 1:52,360,296...52,544,448
Ensembl chr 1:52,360,296...52,544,450
|
|
G |
Pde1b |
phosphodiesterase 1B |
increases expression |
EXP ISO |
Haloperidol results in increased expression of PDE1B mRNA; Haloperidol results in increased expression of PDE1B protein |
CTD |
PMID:14647396 PMID:18222493 |
|
NCBI chr 7:145,117,951...145,147,711
Ensembl chr 7:145,117,951...145,145,376
|
|
G |
Pde4a |
phosphodiesterase 4A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PDE4A protein |
CTD |
PMID:20222156 |
|
NCBI chr 8:22,189,533...22,234,036
Ensembl chr 8:22,189,600...22,233,748
|
|
G |
Penk |
proenkephalin |
multiple interactions increases expression |
ISO EXP |
3,4-dicarboxyphenylglycine promotes the reaction [Haloperidol results in increased expression of PENK mRNA]; Docosahexaenoic Acids inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Tretinoin inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] Haloperidol results in increased expression of PENK mRNA; Haloperidol results in increased expression of PENK protein 1-aminocyclopentane-1,2,4-tricarboxylic acid inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 1-aminoindan-1,5-dicarboxylic acid inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 2-(2,3-dicarboxycyclopropyl)glycine promotes the reaction [Haloperidol results in increased expression of PENK mRNA]; 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Memantine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] |
CTD |
PMID:3838946 PMID:7637876 PMID:12373537 PMID:12727308 PMID:12834887 PMID:12887421 PMID:14603264 PMID:14642644 PMID:15215559 PMID:17224239 |
|
NCBI chr 5:17,056,412...17,061,762
Ensembl chr 5:17,056,419...17,061,837
|
|
G |
Per1 |
period circadian regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PER1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr10:55,681,761...55,696,557
Ensembl chr10:55,687,050...55,695,994
|
|
G |
Pfdn5 |
prefoldin subunit 5 |
increases expression |
ISO |
Haloperidol results in increased expression of PFDN5 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:143,924,662...143,929,400
Ensembl chr 7:143,924,662...143,929,397
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
EXP |
Haloperidol results in increased expression of PFKP mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:68,510,765...68,574,387
Ensembl chr17:68,511,064...68,559,471
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of PGK1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr X:77,263,399...77,279,373
Ensembl chr X:77,263,359...77,279,367
|
|
G |
Phactr1 |
phosphatase and actin regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PHACTR1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr17:23,245,423...23,761,207
|
|
G |
Picalm |
phosphatidylinositol binding clathrin assembly protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of PICALM mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:154,377,229...154,458,966
Ensembl chr 1:154,377,247...154,458,425
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PIK3R3 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:135,069,972...135,145,633
Ensembl chr 5:135,074,297...135,142,488
|
|
G |
Pkib |
cAMP-dependent protein kinase inhibitor beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PKIB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr20:40,616,868...40,712,598
Ensembl chr20:40,618,128...40,712,592
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
EXP |
Haloperidol results in increased expression of PKM mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Plp1 |
proteolipid protein 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PLP1 mRNA |
CTD |
PMID:17177202 PMID:18797397 |
|
NCBI chr X:107,494,326...107,511,355
Ensembl chr X:107,496,072...107,511,348
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPM1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:94,433,658...94,484,979
Ensembl chr 6:94,429,068...94,484,351
|
|
G |
Ppm1b |
protein phosphatase, Mg2+/Mn2+ dependent, 1B |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPM1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:8,219,385...8,280,127
Ensembl chr 6:8,218,696...8,280,124
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1CB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:23,548,507...23,581,136
Ensembl chr 6:23,549,317...23,581,052
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1CC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:39,864,302...39,882,030
Ensembl chr12:39,864,295...39,882,030
|
|
G |
Ppp1r1a |
protein phosphatase 1, regulatory (inhibitor) subunit 1A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:145,146,480...145,154,131
Ensembl chr 7:145,146,481...145,154,131
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases phosphorylation |
ISO |
Haloperidol results in increased phosphorylation of PPP1R1B protein |
CTD |
PMID:12871586 |
|
NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
|
|
G |
Ppp1r2 |
protein phosphatase 1, regulatory (inhibitor) subunit 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr11:72,748,789...73,034,683
Ensembl chr11:73,022,063...73,034,682
|
|
G |
Ppp1r9b |
protein phosphatase 1, regulatory subunit 9B |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R9B protein |
CTD |
PMID:16844384 |
|
NCBI chr10:82,800,704...82,816,735
Ensembl chr10:82,800,704...82,816,731
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2CA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:37,534,449...37,554,861
Ensembl chr10:37,535,871...37,554,664
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2CB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr16:62,273,276...62,294,767
Ensembl chr16:62,273,276...62,294,769
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
EXP |
Haloperidol results in increased expression of PPP2R1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:60,717,386...60,736,629
Ensembl chr 1:60,717,386...60,736,609
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2R2A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr15:43,673,958...43,733,182
Ensembl chr15:43,673,960...43,733,182
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions decreases expression |
EXP |
[Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Haloperidol results in decreased expression of PPP3CA mRNA; Haloperidol results in decreased expression of PPP3CA protein |
CTD |
PMID:16033416 |
|
NCBI chr 2:241,909,332...242,186,861
Ensembl chr 2:241,909,832...242,184,854
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
ISO |
Haloperidol results in decreased expression of PPP5C mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:78,944,054...78,968,361
Ensembl chr 1:78,944,040...78,968,329
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
increases expression |
EXP |
Haloperidol results in increased expression of PRKACA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
increases expression |
EXP |
Haloperidol results in increased expression of PRKACB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:252,602,197...252,691,886
Ensembl chr 2:252,605,307...252,691,886
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions increases expression |
EXP |
Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] Haloperidol results in increased expression of PRKAR2A mRNA; Haloperidol results in increased expression of PRKAR2A protein |
CTD |
PMID:11907174 |
|
NCBI chr 8:117,486,085...117,548,768
Ensembl chr 8:117,486,083...117,546,370
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] Haloperidol results in increased expression of PRKAR2B mRNA; Haloperidol results in increased expression of PRKAR2B protein Haloperidol results in decreased expression of PRKAR2B mRNA |
CTD |
PMID:11907174 PMID:15860345 |
|
NCBI chr 6:51,265,509...51,356,383
Ensembl chr 6:51,265,515...51,356,383
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions increases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein Haloperidol results in increased expression of PRKCB mRNA |
CTD |
PMID:15860345 PMID:15967061 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Prkce |
protein kinase C, epsilon |
increases expression |
EXP |
Haloperidol results in increased expression of PRKCE mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prkcz |
protein kinase C, zeta |
increases expression |
EXP |
Haloperidol results in increased expression of PRKCZ mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:172,658,071...172,769,492
Ensembl chr 5:172,658,748...172,769,421
|
|
G |
Prl |
prolactin |
affects expression increases secretion multiple interactions increases expression |
ISO EXP |
Haloperidol affects the expression of PRL protein Haloperidol results in increased secretion of PRL protein Haloperidol inhibits the reaction [Aripiprazole results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [talipexole results in decreased secretion of PRL protein]; LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)- inhibits the reaction [Haloperidol results in increased expression of PRL protein]; Triptorelin Pamoate inhibits the reaction [Haloperidol results in increased expression of PRL protein] |
CTD |
PMID:1304992 PMID:1380082 PMID:2136057 PMID:3019639 PMID:3158510 PMID:3883215 PMID:3906589 PMID:7018927 PMID:7214106 PMID:7348089 PMID:7670571 PMID:8613910 PMID:8915564 PMID:9090331 PMID:9128918 PMID:9265911 PMID:9265916 PMID:9376336 PMID:9572212 PMID:10661492 PMID:11048906 PMID:11071396 PMID:11997696 PMID:15289996 PMID:15638391 PMID:16282852 PMID:18521575 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prpf38b |
pre-mRNA processing factor 38B |
decreases expression |
ISO |
Haloperidol results in decreased expression of PRPF38B mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:211,706,245...211,715,271
Ensembl chr 2:211,706,228...211,715,311
|
|
G |
Prrc2a |
proline-rich coiled-coil 2A |
decreases expression |
ISO |
Haloperidol results in decreased expression of PRRC2A mRNA |
CTD |
PMID:18797397 |
|
NCBI chr20:5,139,881...5,155,371
Ensembl chr20:5,139,882...5,155,293
|
|
G |
Psmb9 |
proteasome 20S subunit beta 9 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PSMB9 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr20:3,973,424...3,978,845
Ensembl chr20:3,973,420...3,978,845
|
|
G |
Ptms |
parathymosin |
increases expression |
ISO |
Haloperidol results in increased expression of PTMS mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:157,435,371...157,439,507
Ensembl chr 4:157,435,373...157,439,507
|
|
G |
Pvalb |
parvalbumin |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [Phencyclidine results in decreased expression of PVALB mRNA] |
CTD |
PMID:12589379 |
|
NCBI chr 7:119,428,657...119,443,674
Ensembl chr 7:119,429,019...119,441,487
|
|
G |
Qk |
quaking |
increases expression |
ISO |
Haloperidol results in increased expression of QKI mRNA alternative form |
CTD |
PMID:19335891 |
|
NCBI chr 1:50,983,647...51,050,692
|
|
G |
Rab10 |
RAB10, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB10 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:27,668,387...27,721,120
Ensembl chr 6:27,668,403...27,721,120
|
|
G |
Rab11a |
RAB11a, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB11A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:70,192,975...70,215,719
Ensembl chr 8:70,192,975...70,215,719
|
|
G |
Rab12 |
RAB12, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB12 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 9:114,683,985...114,709,613
Ensembl chr 9:114,684,039...114,709,546
|
|
G |
Rab28 |
RAB28, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB28 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:73,888,968...73,963,209
Ensembl chr14:73,889,213...73,963,202
|
|
G |
Rab4a |
RAB4A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB4A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:56,585,598...56,613,078
Ensembl chr19:56,585,767...56,613,075
|
|
G |
Rab6a |
RAB6A, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB6A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:165,624,973...165,664,201
Ensembl chr 1:165,625,058...165,664,192
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB7A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:119,910,461...119,963,065
Ensembl chr 4:119,910,478...119,959,173
|
|
G |
Rab8a |
RAB8A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB8A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr16:19,355,047...19,376,776
Ensembl chr16:19,355,048...19,376,776
|
|
G |
Rac1 |
Rac family small GTPase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of RAC1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
|
|
G |
Rala |
RAS like proto-oncogene A |
increases expression |
EXP |
Haloperidol results in increased expression of RALA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
|
|
G |
Ralb |
RAS like proto-oncogene B |
increases expression |
EXP |
Haloperidol results in increased expression of RALB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:35,494,716...35,531,503
Ensembl chr13:35,494,721...35,511,020
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAP1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:60,850,406...60,878,226
Ensembl chr 7:60,853,930...60,860,990
|
|
G |
Rapgef4 |
Rap guanine nucleotide exchange factor 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RAPGEF4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 3:58,632,338...58,925,127
Ensembl chr 3:58,632,476...58,924,038
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
EXP |
Haloperidol results in increased expression of RARB mRNA alternative form |
CTD |
PMID:11564422 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rasgrf1 |
RAS protein-specific guanine nucleotide-releasing factor 1 |
affects localization |
EXP |
Haloperidol affects the localization of RASGRF1 protein |
CTD |
PMID:17092607 |
|
NCBI chr 8:97,277,250...97,405,095
Ensembl chr 8:97,277,456...97,405,102
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of RASGRP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:108,984,029...109,044,420
Ensembl chr 3:108,984,029...109,044,420
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
EXP |
Haloperidol results in increased expression of RELA protein |
CTD |
PMID:18554768 PMID:18590723 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Reln |
reelin |
decreases expression |
EXP |
Haloperidol results in decreased expression of RELN mRNA; Haloperidol results in decreased expression of RELN protein |
CTD |
PMID:19359144 |
|
NCBI chr 4:9,347,533...9,774,257
Ensembl chr 4:9,347,528...9,773,670
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Haloperidol results in increased expression of RGS2 mRNA |
CTD |
PMID:11409749 PMID:11516571 |
|
NCBI chr13:60,846,458...60,849,061
Ensembl chr13:60,846,308...60,849,094
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
increases expression |
EXP |
Haloperidol results in increased expression of RGS4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:88,054,817...88,061,108
Ensembl chr13:88,054,817...88,061,108
|
|
G |
Rgs8 |
regulator of G-protein signaling 8 |
increases expression |
EXP |
Haloperidol results in increased expression of RGS8 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:71,086,654...71,141,820
Ensembl chr13:71,086,745...71,141,075
|
|
G |
Rgs9 |
regulator of G-protein signaling 9 |
affects response to substance |
ISO |
RGS9 affects the susceptibility to Haloperidol |
CTD |
PMID:15728856 |
|
NCBI chr10:97,509,971...97,582,188
Ensembl chr10:97,509,971...97,582,188
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
EXP |
Haloperidol results in decreased expression of RHOA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
G |
Rims1 |
regulating synaptic membrane exocytosis 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of RIMS1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:28,440,408...28,973,246
Ensembl chr 9:28,442,229...28,973,246
|
|
G |
Rorb |
RAR-related orphan receptor B |
decreases expression |
EXP |
Haloperidol results in decreased expression of RORB mRNA |
CTD |
PMID:11564422 |
|
NCBI chr 1:234,252,757...234,442,597
Ensembl chr 1:234,252,757...234,435,839
|
|
G |
Rplp2 |
ribosomal protein lateral stalk subunit P2 |
increases expression |
ISO |
Haloperidol results in increased expression of RPLP2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:214,428,280...214,430,551
Ensembl chr 1:214,428,526...214,430,515
|
|
G |
Rps10 |
ribosomal protein S10 |
increases expression |
ISO |
Haloperidol results in increased expression of RPS10 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:7,215,762...7,220,331
Ensembl chr20:7,215,774...7,219,548
|
|
G |
Rrad |
RRAD, Ras related glycolysis inhibitor and calcium channel regulator |
increases expression |
EXP |
Haloperidol results in increased expression of RRAD mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:561,696...564,929
Ensembl chr19:561,727...564,930
|
|
G |
Rtn4 |
reticulon 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RTN4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr14:114,126,931...114,174,459
Ensembl chr14:114,126,943...114,174,458
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects response to substance increases expression |
ISO EXP |
RXRG protein affects the susceptibility to Haloperidol Haloperidol results in increased expression of RXRG mRNA alternative form |
CTD |
PMID:10336693 PMID:11564422 |
|
NCBI chr13:85,818,473...85,868,555
Ensembl chr13:85,818,427...85,868,552
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
decreases expression |
ISO |
Haloperidol results in decreased expression of S100A9 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
Haloperidol results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:46,525,406...46,537,014
Ensembl chr 8:46,525,400...46,537,050
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Haloperidol results in increased expression of SCD mRNA |
CTD |
PMID:16027736 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Serpini1 |
serpin family I member 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SERPINI1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:174,013,058...174,111,693
Ensembl chr 2:174,013,288...174,111,752
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of SGK1 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
increases expression |
ISO |
Haloperidol results in increased expression of SLC17A6 mRNA; Haloperidol results in increased expression of SLC17A6 protein |
CTD |
PMID:18155072 |
|
NCBI chr 1:106,980,463...107,038,717
Ensembl chr 1:106,998,623...107,038,704
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
affects response to substance |
ISO |
SLC17A8 protein affects the susceptibility to Haloperidol |
CTD |
PMID:18278042 |
|
NCBI chr 7:30,215,231...30,274,993
Ensembl chr 7:30,216,104...30,274,984
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
affects binding |
ISO |
Haloperidol binds to SLC18A2 protein |
CTD |
PMID:7912402 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:12873733 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:12873733 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SLC1A3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:57,860,881...57,935,363
Ensembl chr 2:57,860,834...57,935,363
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Haloperidol inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:23770354 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
Haloperidol results in increased expression of SLC2A4 mRNA |
CTD |
PMID:16002093 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Slc39a7 |
solute carrier family 39 member 7 |
increases expression |
ISO |
Haloperidol results in increased expression of SLC39A7 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:3,819,416...3,822,788
Ensembl chr20:3,819,414...3,822,778
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions increases expression |
ISO EXP |
SLC6A3 protein promotes the reaction [Haloperidol results in increased expression of NTS mRNA] Haloperidol results in increased expression of SLC6A3 protein |
CTD |
PMID:14698760 PMID:17069804 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
increases expression |
EXP |
Haloperidol results in increased expression of SLC6A4 |
CTD |
PMID:12007678 |
|
NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects response to substance affects expression |
ISO EXP |
SNAP25 gene SNP affects the susceptibility to Haloperidol Haloperidol affects the expression of SNAP25 mRNA |
CTD |
PMID:15823421 PMID:15860345 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
G |
Snrpd2 |
small nuclear ribonucleoprotein D2 polypeptide |
increases expression |
ISO |
Haloperidol results in increased expression of SNRPD2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:80,057,140...80,059,990
Ensembl chr 1:80,056,755...80,059,996
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression decreases expression multiple interactions |
EXP |
Haloperidol results in increased expression of SOD1 mRNA Haloperidol results in decreased expression of SOD1 protein Clozapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]; Haloperidol results in decreased activity of and results in decreased expression of SOD1 protein; olanzapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein] |
CTD |
PMID:12482469 PMID:12752374 PMID:16564057 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
Haloperidol results in decreased expression of SOD2 mRNA; Haloperidol results in decreased expression of SOD2 protein Haloperidol results in decreased activity of and results in decreased expression of SOD2 protein |
CTD |
PMID:12482469 PMID:15860345 PMID:16564057 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sod3 |
superoxide dismutase 3 |
increases expression |
EXP |
Haloperidol results in increased expression of SOD3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Haloperidol results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:17052361 |
|
NCBI chr 7:123,381,082...123,438,605
Ensembl chr 7:123,381,077...123,438,603
|
|
G |
Strn4 |
striatin 4 |
increases expression |
ISO |
Haloperidol results in increased expression of STRN4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:78,739,930...78,765,696
Ensembl chr 1:78,735,678...78,765,692
|
|
G |
Stx1a |
syntaxin 1A |
increases expression |
EXP |
Haloperidol results in increased expression of STX1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:24,682,050...24,710,002
Ensembl chr12:24,682,041...24,710,019
|
|
G |
Stx1b |
syntaxin 1B |
affects expression |
EXP |
Haloperidol affects the expression of STX1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:199,251,842...199,270,465
Ensembl chr 1:199,251,844...199,270,627
|
|
G |
Stx4 |
syntaxin 4 |
increases expression |
EXP |
Haloperidol results in increased expression of STX4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:199,287,384...199,295,606
Ensembl chr 1:199,287,710...199,294,979
|
|
G |
Stx5 |
syntaxin 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of STX5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:224,939,497...224,955,658
Ensembl chr 1:224,939,497...224,955,657
|
|
G |
Stx7 |
syntaxin 7 |
decreases expression |
EXP |
Haloperidol results in decreased expression of STX7 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:22,241,655...22,281,850
Ensembl chr 1:22,241,661...22,281,788
|
|
G |
Stx8 |
syntaxin 8 |
affects expression |
EXP |
Haloperidol affects the expression of STX8 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:54,512,922...54,753,302
Ensembl chr10:54,512,983...54,753,302
|
|
G |
Supt3h |
SPT3 homolog, SAGA and STAGA complex component |
increases expression |
EXP |
Haloperidol results in increased expression of SUPT3H mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 9:18,249,565...18,604,814
Ensembl chr 9:18,319,246...18,371,856
|
|
G |
Syn2 |
synapsin II |
increases expression |
EXP |
Haloperidol results in increased expression of SYN2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:147,037,179...147,195,096
Ensembl chr 4:147,037,179...147,195,096
|
|
G |
Sypl1 |
synaptophysin-like 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SYPL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:52,265,920...52,286,037
Ensembl chr 6:52,265,930...52,285,029
|
|
G |
Syt11 |
synaptotagmin 11 |
increases expression |
EXP |
Haloperidol results in increased expression of SYT11 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:188,112,301...188,138,180
Ensembl chr 2:188,112,286...188,138,177
|
|
G |
Syt3 |
synaptotagmin 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SYT3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:100,379,236...100,407,862
Ensembl chr 1:100,379,186...100,408,083
|
|
G |
Syt4 |
synaptotagmin 4 |
affects expression |
EXP |
Haloperidol affects the expression of SYT4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr18:24,172,580...24,181,989
Ensembl chr18:24,172,587...24,182,012
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
EXP |
Haloperidol results in increased expression of TAC1 mRNA |
CTD |
PMID:10974607 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Haloperidol results in decreased expression of TAGLN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
decreases expression |
EXP |
Haloperidol results in decreased expression of TAP1 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr20:3,979,302...3,989,669
Ensembl chr20:3,979,035...3,989,669
|
|
G |
Tatdn1 |
TatD DNase domain containing 1 |
increases expression |
ISO |
Haloperidol results in increased expression of TATDN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:98,782,164...98,813,001
Ensembl chr 7:98,782,178...98,804,499
|
|
G |
Tf |
transferrin |
decreases expression |
ISO |
Haloperidol results in decreased expression of TRF mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Haloperidol results in increased expression of TH protein |
CTD |
PMID:17028028 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Thra |
thyroid hormone receptor alpha |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of THRA mRNA alternative form Haloperidol results in increased expression of THRA mRNA alternative form |
CTD |
PMID:11564422 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
Haloperidol affects the reaction [Phencyclidine affects the expression of TNF mRNA] Haloperidol results in increased expression of TNF protein |
CTD |
PMID:16478754 PMID:18554768 PMID:18590723 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnik |
TRAF2 and NCK interacting kinase |
decreases expression |
ISO |
Haloperidol results in decreased expression of TNIK mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:113,984,599...114,391,805
Ensembl chr 2:113,984,646...114,384,894
|
|
G |
Tor1a |
torsin family 1, member A |
affects response to substance |
ISO |
TOR1A gene mutant form affects the susceptibility to Haloperidol |
CTD |
PMID:20227500 |
|
NCBI chr 3:9,800,322...9,807,318
Ensembl chr 3:9,800,322...9,807,328
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
Haloperidol results in increased expression of TP53 mRNA; Haloperidol results in increased expression of TP53 protein |
CTD |
PMID:16462815 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of TPI1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905
|
|
G |
Trim2 |
tripartite motif-containing 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TRIM2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:183,145,096...183,223,819
Ensembl chr 2:183,145,089...183,213,228
|
|
G |
Trim23 |
tripartite motif-containing 23 |
decreases expression |
EXP |
Haloperidol results in decreased expression of TRIM23 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:34,255,300...34,288,140
Ensembl chr 2:34,255,305...34,288,139
|
|
G |
Uba52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
increases expression |
ISO |
Haloperidol results in increased expression of UBA52 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr16:20,668,925...20,671,127
Ensembl chr16:20,668,971...20,671,127
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
increases expression |
ISO |
Haloperidol results in increased expression of UBE2R2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 5:57,472,315...57,530,973
Ensembl chr 5:57,472,315...57,530,987
|
|
G |
Ugt8 |
UDP glycosyltransferase 8 |
decreases expression |
ISO |
Haloperidol results in decreased expression of UGT8A mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 2:229,644,373...229,718,678
Ensembl chr 2:229,644,382...229,718,659
|
|
G |
Unc13a |
unc-13 homolog A |
decreases expression |
EXP |
Haloperidol results in decreased expression of UNC13A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr16:20,056,398...20,103,951
Ensembl chr16:20,056,765...20,097,287
|
|
G |
Uqcr11 |
ubiquinol-cytochrome c reductase, complex III subunit XI |
increases expression |
ISO |
Haloperidol results in increased expression of UQCR11 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:12,171,146...12,175,838
Ensembl chr 7:12,171,185...12,175,835
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of VAMP1 mRNA Haloperidol results in increased expression of VAMP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,726,941...157,733,644
Ensembl chr 4:157,726,941...157,733,643
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of VAMP2 mRNA Haloperidol results in increased expression of VAMP2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:55,675,171...55,679,405
Ensembl chr10:55,675,575...55,679,450
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of VIPR2 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 6:143,932,960...144,009,476
Ensembl chr 6:143,938,040...144,008,072
|
|
G |
Vldlr |
very low density lipoprotein receptor |
increases expression |
EXP |
Haloperidol results in increased expression of VLDLR protein |
CTD |
PMID:19359144 |
|
NCBI chr 1:245,236,819...245,273,688
Ensembl chr 1:245,237,736...245,269,205
|
|
G |
Vsnl1 |
visinin-like 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of VSNL1 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 6:37,001,360...37,121,969
Ensembl chr 6:37,001,356...37,122,023
|
|
G |
Wbp1l |
WW domain binding protein 1-like |
decreases expression |
ISO |
Haloperidol results in decreased expression of WBP1L mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:266,358,728...266,415,296
Ensembl chr 1:266,358,728...266,415,296
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Haloperidol results in increased expression of WIPI1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr10:97,859,730...97,896,949
Ensembl chr10:97,859,727...97,896,525
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
miglustat inhibits the reaction [ST8SIA1 protein results in increased expression of BCL2 protein] |
CTD |
PMID:11574545 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Canx |
calnexin |
multiple interactions |
ISO |
miglustat inhibits the reaction [CANX protein binds to CFTR protein mutant form] |
CTD |
PMID:18230692 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat results in increased activity of CFTR protein mutant form]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; miglustat inhibits the reaction [CANX protein binds to CFTR protein mutant form]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form] |
CTD |
PMID:18230692 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
ISO |
miglustat inhibits the reaction [[ST8SIA1 protein affects the abundance of Gangliosides] which results in decreased expression of PAWR protein] |
CTD |
PMID:11574545 |
|
NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
|
|
G |
St8sia1 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 |
multiple interactions |
ISO |
miglustat inhibits the reaction [[ST8SIA1 protein affects the abundance of Gangliosides] which results in decreased expression of PAWR protein]; miglustat inhibits the reaction [ST8SIA1 protein results in increased expression of BCL2 protein] |
CTD |
PMID:11574545 |
|
NCBI chr 4:177,065,266...177,195,942
Ensembl chr 4:177,065,168...177,196,180
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
multiple interactions |
ISO |
[miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Gangliosides; [miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Glucosylceramides |
CTD |
PMID:10037475 |
|
NCBI chr 5:76,376,722...76,419,564
Ensembl chr 5:76,386,836...76,419,560
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
periciazine binds to and results in decreased activity of AR protein |
CTD |
PMID:17606915 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
periciazine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|